NCI Cancer Bulletin: A Trusted Source for Cancer Research News
NCI Cancer Bulletin: A Trusted Source for Cancer Research News
April 17, 2007 • Volume 4 / Number 15 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Article

Antiangiogenic Agent Shows Promise against Glioblastoma

An experimental antiangiogenesis drug may improve the treatment of the most common and deadly type of adult brain cancer, researchers from Massachusetts General Hospital and Harvard Medical School reported this week at the American Association for Cancer Research (AACR) annual meeting in Los Angeles.

The promising clinical results were buttressed by imaging and biomarker analyses that support a theory that the value of antiangiogenic agents may not be limited to halting the development of blood vessels that feed tumors, but that the drugs also can "normalize" them to the point where the delivery of standard treatments to the tumor may be improved.

AACR Centennial 1907-2007 The research team presented updated data from a phase II clinical trial involving 31 patients with glioblastoma that had recurred after standard treatment of chemotherapy and radiation. Daily use of the experimental agent, AZD2171, an inhibitor of vascular endothelial growth factor (VEGF) receptors, improved progression-free survival compared with what is historically seen in patients with recurrent glioblastoma, 111 days vs. 63 days. The drug had a more modest improvement in overall survival compared with historical controls, 211 days vs. 179 days. In addition, 9 of the first 16 patients achieved partial responses as measured by at least a 50-percent reduction in tumor contrast enhancement by imaging.

"The results are encouraging," said the study's lead investigator, Dr. Tracy Batchelor, chief of neuro-oncology at Massachusetts General Hospital Cancer Center. "All of the arrows are pointing in the right direction."

Even so, Dr. Batchelor warned, this was a small number of patients in a nonrandomized trial, so the results should be interpreted with an abundance of caution.

According to Dr. Percy Ivy of NCI's Cancer Therapy Evaluation Program, the study also reached another important metric: 27.6 percent of patients were alive and with no signs of disease progression at 6 months, compared with a historic benchmark of approximately 15 percent with standard therapy. That suggests further studies are warranted.

"This is exciting because, as a single agent, [AZD2171] has shown some evidence of activity in a disease that is uniformly fatal," Dr. Ivy said. "And the evidence is sufficient to start exploring combinations and determining if this represents a new advance in treatment."

In addition to the improved survival results, in some patients the use of AZD2171 remedied a significant problem associated with glioblastoma: swelling in the brain caused by fluid retention, known as edema. As a result, many of the patients were able to reduce or halt altogether the use of steroids to treat the edema, which carry their own debilitating side effects.

 
 

Read more AACR research highlights.

 
The drug's impact on edema, said study team member Dr. Rakesh K. Jain, was one of several pieces of evidence that the drug very rapidly creates a window of "vascular normalization" in the tumor. In addition to blocking the formation of small, weak blood vessels that feed the tumor, explained Dr. Jain, the study showed that, as soon as 24 hours after the first dose, AZD2171 also improved the structure and function of some larger, leaky vessels - normalizing them - for at least 28 days. In some cases, this normalization lasted up to 4 months.

Evidence for normalization was acquired through a novel application of imaging studies that allowed a careful comparison of blood vessels on the unaffected side of the brain with vessels in and around the tumor. Molecular biomarker analyses, meanwhile, showed that the expression of two proteins, bFGF and SDF1α, correlated with tumor progression and reversion of vessel diameter to an abnormal, enlarged state during treatment.

These findings, Dr. Jain continued, suggest that bFGF and SDF1α are pro-angiogenic reinforcements called to action to help tumors escape anti-VEGF treatment. Although animal model studies had indicated bFGF was likely involved in angiogenesis, SDF1α's involvement is a new finding.

Based on these results, NCI has approved an early-phase clinical trial to evaluate AZD2171 in combination with standard therapy of radiation and temozolomide in newly diagnosed glioblastoma patients. And Dr. Batchelor will lead a randomized phase III trial supported by AstraZeneca that will test AZD2171 in combination with chemotherapy in patients with recurrent glioblastoma. That trial has been submitted to the FDA for approval, Dr. Batchelor said, with the hope of enrolling patients by the end of the year.

By Carmen Phillips